Publikationen (45) Publikationen von Amaia Vilas Zornoza

filter_list

2023

  1. Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia

    Haematologica, Vol. 108, Núm. 10, pp. 2652-2663

  2. Revealing cell populations catching the early stages of human embryo development in naive pluripotent stem cell cultures

    Stem Cell Reports, Vol. 18, Núm. 1, pp. 64-80

  3. The transcriptional regulator Sin3A balances IL-17A and Foxp3 expression in primary CD4 T cells

    EMBO Reports, Vol. 24, Núm. 5

  4. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution

    eLife, Vol. 12

2022

  1. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells

    Cell Metabolism, Vol. 34, Núm. 6, pp. 857-873.e9

  2. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39

  3. In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria

    Molecular Therapy - Methods and Clinical Development, Vol. 25, pp. 137-146

  4. One-Step In Vitro Generation of ETV2-Null Pig Embryos

    Animals, Vol. 12, Núm. 14

  5. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

  6. The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells

    Leukemia, Vol. 36, Núm. 8, pp. 1969-1979

  7. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

    Nature Communications, Vol. 13, Núm. 1

2021

  1. Activation-induced deaminase is critical for the establishment of DNA methylation patterns prior to the germinal center reaction

    Nucleic Acids Research, Vol. 49, Núm. 9, pp. 5057-5073

  2. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma

    Leukemia, Vol. 35, Núm. 5, pp. 1438-1450

  3. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  4. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with in Vivo Efficacy in Multiple Myeloma

    Journal of Medicinal Chemistry, Vol. 64, Núm. 6, pp. 3392-3426

  5. Immunologic characterization of COVID-19 patients with hematological cancer

    Haematologica

  6. Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients

    Frontiers in Immunology, Vol. 12

  7. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

2020

  1. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

    Genome Research, Vol. 30, Núm. 9, pp. 1217-1227

  2. Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD)

    Journal of Extracellular Vesicles, Vol. 9, Núm. 1